Northern Spirits Biosciences Group (NSBG) positions itself as a vertically integrated cannabis company with a heavy emphasis on R&D and standardization rather than simple commodity cultivation. The deck, dating from early 2019, outlines a clear path from facility expansion in Uxbridge to pharmaceutical drug development and global expansion into Europe. While the market data is dated, the deck effectively communicates a transition from a production-heavy model to a science-led branding and pharmaceutical play. However, the provided slides lack a specific funding ask, detailed unit economics, a…
Key takeaways
- The company targets a Canadian cannabis ancillary market estimated by Deloitte to reach up to $22.6 billion annually (Slide 5).
- NSBG aims to move away from being a commodity-based cultivation company to a leading R&D and standardization firm (Slide 17).
- The facility expansion plan includes a 4,000 sq. ft. upgrade in Q1 2019 followed by a 20,000 sq. ft. new build in Q3 2020 (Slide 13).
- Global strategy focuses on entering the European market, specifically mentioning dialogues in the Netherlands and Greece (Slide 9).
- The business is divided into three distinct segments: Consumer Products, Pharmaceuticals, and a Channel Sales Strategy (Slide 21).
- The pharmaceutical division intends to pursue Health Canada and FDA approval for CBD-based treatments (Slide 21).
- The timeline projected clinical trials to begin in Winter 2020 and production expansion to meet demand by Winter 2021 (Slide 25).
- Financial assumptions are built on four pillars: Production, Expansion, Branding, and Science-led growth (Slide 29).
Introduction and Market Context
Slide 1: Title Slide
The title slide introduces Northern Spirits Biosciences Group (NSBG) with the tagline "Grow With Us." The visual identity utilizes a green and blue color palette, featuring a stylized cannabis leaf integrated with a DNA helix, signaling the company's focus on the intersection of botany and bioscience. The background includes a globe overlaid with molecular structures and urban silhouettes, suggesting a global, industrial-scale ambition.
Slide 5: Canadian Cannabis Market by the Numbers
This slide provides the macro-economic justification for the business. It cites three key figures: $5.6B spent by 4.9 million Canadians on cannabis in 2017 (Statistics Canada); $6.5B in projected legal sales by 2020 (CIBC report); and a massive $22.6B potential for the ancillary market, including testing labs and infused products (Deloitte). By highlighting the ancillary and infused product market as the largest opportunity, NSBG aligns its R&D focus with the highest-value segment of the industry.
Strategic Positioning and Global Reach
Slide 9: Global Footprint
NSBG positions Canada as the only G7 country at the time to fully legalize marijuana, providing a "first-mover advantage." The slide outlines a strategy to serve the North American market from Canadian facilities while simultaneously entering Europe. It specifically mentions dialogues in the Netherlands and Greece for acquisitions and joint ventures. A quote from PwC regarding the earnings potential of emerging overseas markets is used to validate this international expansion.
Slide 13: Uxbridge Facility Expansion Plan
This slide details the physical infrastructure required to meet their goals. It shows a floor plan for "Phase 1," a 4,000 sq. ft. facility upgrade slated for Q1 2019. "Phase 2" is much more ambitious, involving a 20,000 sq. ft. new build scheduled for Q3 2020. The inclusion of architectural renderings and site photos provides tangible evidence of operational planning, though it lacks specific cost estimates for these builds.
Product and Research Strategy
Slide 17: Research and Development
This is a pivotal slide for NSBG's differentiation. They explicitly state that they do not want to be a "commodity based cultivation company." Instead, they aim to be a "leading, vertically integrated R&D and standardization company." The slide critiques the current "primitive" prescription model where doctors lack knowledge of medical marijuana and dosage monitoring is non-existent. NSBG proposes to solve this through in-house R&D and university partnerships, focusing on the science of THC, CBD, Indica, and Sativa to ensure accurate dosage and administration.
Slide 21: Distinct Brand Segments
The business is organized into three pillars: 1. Consumer Products (manufacturing and marketing in-house brands and partnering with non-LP companies in sectors like beverages and beauty); 2. Pharmaceuticals (developing CBD-based medicine for Health Canada and FDA approval); and 3. Channel Sales Strategy (driving growth through e-commerce, national accounts, and private labels while adhering to strict Health Canada advertising rules).
Execution and Financial Outlook
Slide 25: Key Milestones
The roadmap covers a three-year period from 2019 to 2021. Critical path items include the LP application (Jan 2019) , License to Cultivate (Spring 2019) , and License to Produce (Summer 2019) . The later stages of the roadmap shift toward higher-value activities: product innovation in Fall 2019, clinical trials in Winter 2020, and a major capacity expansion in Winter 2021. This timeline is useful for investors to track progress, though, given the date of the deck, these are now historical projections.
Slide 29: Financial Assumptions
Rather than providing a spreadsheet, this slide uses a "growth of a plant" metaphor to explain their financial logic. The four stages are: Production (continuous growth over 3 years), Expansion (acquiring market share via Edmonton and Uxbridge facilities), Branding (generating increased revenue through best-in-class products), and Science (R&D and clinical trials as the final stage of organizational growth). While visually clear, this slide is light on actual financial data, such as burn rate, revenue targets, or margins.
Slide 33: Contact Information
The final slide provides direct contact details for Simon Nasr, CEO , including a phone number, email, and website. The design mirrors the title slide, maintaining brand consistency.
What Northern Spirits Biosciences Group Does Well
The deck excels at differentiation. In a crowded 2019 cannabis market where most companies were focused on "grams produced," NSBG correctly identified that the long-term value lay in R&D, standardization, and pharmaceutical applications. By explicitly stating they are not a commodity company, they appeal to investors looking for intellectual property and higher-margin medical plays. The facility expansion plan is also well-presented, providing a clear visual link between their strategic goals and their physical capacity to execute.
What is Missing from the Deck
The most glaring omission in the provided slides is the Ask . There is no mention of how much capital is being raised, the valuation, or the specific use of funds. Furthermore, the Team Slide is missing from this selection; in a science-heavy R&D play, the credentials of the scientists and researchers are just as important as the CEO. Finally, the Financial Assumptions slide is purely conceptual. Investors typically require a five-year projection including EBITDA, COGS, and customer acquisition costs, especially in a capital-intensive industry like cannabis cultivation and pharmaceuticals.
Founder's Guide: What to Copy
Founders should emulate the way NSBG uses Market Segmentation (Slide 21). By breaking the business into Consumer, Pharma, and Channel Sales, they show a diversified revenue model that isn't dependent on a single market trend. The Milestone Roadmap (Slide 25) is also a strong example of how to present a multi-year execution plan that balances regulatory hurdles with commercial expansion. Lastly, the use of third-party validation (Slide 5 and Slide 9) from reputable sources like Deloitte, CIBC, and PwC adds significant credibility to the market opportunity claims.
Frequently asked questions
- What is the primary business model of Northern Spirits Biosciences Group?
- NSBG describes itself as a vertically integrated R&D and standardization company within the cannabis industry. While they do cultivate high-quality marijuana, their stated goal is to avoid being a mere 'commodity-based cultivation company.' Instead, they focus on in-house R&D and strategic university partnerships to develop standardized drug products and consumer brands.
- How does the company plan to scale its physical operations?
- The company outlined a two-phase expansion for its Uxbridge facility. Phase 1, scheduled for Q1 2019, involved a 4,000 sq. ft. facility upgrade. Phase 2, scheduled for Q3 2020, was a significantly larger 20,000 sq. ft. new build. The deck also mentions acquiring market share through the expansion of production facilities in Edmonton.
- What is NSBG's strategy for the pharmaceutical market?
- The Pharmaceutical Division focuses on developing cannabis-based medicine using CBD as the active pharmaceutical ingredient (API). They aim to treat a wide range of medical conditions and explicitly state their intention to pursue regulatory approvals from both Health Canada and the FDA. This is supported by a planned move into clinical trials.
- What geographic markets is the company targeting?
- The primary focus is the North American market, leveraged by their Canadian headquarters and production facilities. However, they also have a 'Global Footprint' strategy targeting Europe. The deck mentions open discussions with companies in the Netherlands and Greece for potential strategic acquisitions and joint venture partnerships.
- What are the major milestones listed in the deck?
- Key milestones include submitting a Licensed Producer (LP) application in January 2019, obtaining a license to cultivate in Spring/Summer 2019, and a license to produce by Summer 2019. Long-term goals included beginning clinical trials in Winter 2020 and a major production capacity expansion in Winter 2021.
